Filters applied:
Did You Mean? ?
one result

 

  • Book
    edited by Kinam Park.
    Digital : ScienceDirect2013
    Part I Fundamentals of biomaterials for cancer therapeutics; 1 Introduction to biomaterials for cancer therapeutics; 1.1 Introduction; 1.2 Biomaterials used in cancer therapeutics; 1.3 Materials used in anticancer formulations; 1.4 Conclusion and future trends; 1.5 References; 2 Cancer cell biology; 2.1 Introduction; 2.2 Public perception and misunderstanding of cancer cell activity; 2.3 The 'War on Cancer'; 2.4 The genetic basis of cancer; 2.5 Cancer interface with the environment; 2.6 Cancer cells as moving targets; 2.7 Conclusion and future trends; 2.8 References; 3 Targeted drug delivery for cancer therapy; 3.1 Introduction; 3.2 Current paradigm; 3.3 Challenges to current paradigm; 3.4 Conclusion and future trends; 3.5 References; Part II Synthetic vaccines, proteins, and polymers for cancer therapeutics; 4 Chemical synthesis of carbohydrate-based vaccines against cancers; 4.1 Introduction; 4.2 Semi-synthetic vaccines; 4.3 Fully synthetic vaccines; 4.4 Conclusion and future trends; 4.5 References; 5 Generating functional mutant proteins to create highly bioactive anticancer biopharmaceuticals; 5.1 Introduction; 5.2 Artificial proteins for cancer therapy; 5.3 How to create functional mutant proteins as beneficial therapeutics; 5.4 Mutant TNF(alpha) for cancer therapy; 5.5 Conclusion and future trends; 5.6 Sources of further information and advice; 5.7 References; 6 Polymer therapeutics for treating cancer; 6.1 Introduction; 6.2 Polyamines and polyamine analogs; 6.3 Polymeric P-glycoprotein (Pgp) inhibitors; 6.4 Conclusion and future trends; 6.5 Acknowledgment; 6.6 References; Part III Theranosis and drug delivery systems for cancer therapeutics; 7 Nanotechnology for cancer screening and diagnosis; 7.1 Introduction; 7.2 Nanotechnology for cancer diagnosis; 7.3 Nanotechnology-based biosensing platforms; 7.4 Nanotechnology for biosensing -- early detection of cancer; 7.5 Nanotechnology for cancer imaging; 7.6 Concerns with using nanomaterials; 7.7 Conclusion and future trends; 7.8 References; 8 Synergistically integrated nanomaterials for multimodal cancer cell imaging; 8.1 Introduction; 8.2 Nanomaterial-based multifunctional imaging probes; 8.3 Nanoparticles with exogenous imaging ligands; 8.4 Nanoparticles with endogenous contrast; 8.5 Cocktail injection; 8.6 Conclusion; 8.7 References; 9 Hybrid nanocrystal as a versatile platform for cancer theranostics; 9.1 Introduction; 9.2 Imaging modality; 9.3 Developing theranostic systems; 9.4 Hybrid nanocrystal as theranostic platform; 9.5 Conclusion; 9.6 Acknowledgment; 9.7 References; 10 Embolisation devices from biomedical polymers for intra-arterial occlusion and drug delivery in the treatment of cancer; 10.1 Introduction; 10.2 Biomedical polymers and embolisation agents; 10.3 Particulate embolisation agents; 10.4 Drug-eluting embolisation beads; 10.5 Polymer structure, form and property relationships; 10.6 Experience with drug-eluting embolisation beads; 10.7 Conclusions and future trends; 10.8 Acknowledgement; 10.9 References; 11 Small interfering RNAs (siRNAs) as cancer therapeutics; 11.1 Introduction; 11.2 Prerequisites for siRNAs cancer therapeutics; 11.3 Delivery systems of anticancer siRNAs; 11.4 Current challenges for clinical trials; 11.5 Conclusion; 11.6 Acknowledgement; 11.7 References; 12 Reverse engineering of the low temperature-sensitive liposome (LTSL) for treating cancer; 12.1 Introduction; 12.2 What is reverse engineering?; 12.3 Investigating the thermal-sensitive liposome's performance-in-service; 12.4 Defining the function of the liposome; 12.5 Component design: mechanism of action; 12.6 Selecting the most appropriate material when designing the Dox-LTSL; 12.7 Analysis of materials performance in the design; 12.8 Specification sheet; 12.9 Production; 12.10 Prototypes; 12.11 Further development; 12.12 Conclusion and future trends; 12.13 Acknowledgements; 12.14 References; 13 Gold nanoparticles (GNPs) as multifunctional materials for cancer treatment; 13.1 Introduction; 13.2 Physical properties of gold nanoparticles; 13.3 Surface chemistry of GNPs; 13.4 GNPs as vehicles for drug delivery; 13.5 GNPs in biomedical imaging and theranostics; 13.6 GNPs as radiosensitizing agents; 13.7 Challenges in the development of GNPs as therapeutic agents; 13.8 Conclusion and future trends; 13.9 Acknowledgments; 13.10 Bibliography; 14 Multifunctional nanosystems for cancer therapy; 14.1 Introduction; 14.2 Design of multifunctional nanosystems; 14.3 Illustrative examples of multifunctional nanosystems for tumor-targeted therapies; 14.4 Polymeric nanosystems; 14.5 Lipid nanosystems; 14.6 Hybrid nanosystems; 14.7 Regulatory and clinical perspectives; 14.8 Conclusions; 14.9 References; Part IV Biomaterial therapeutics and cancer cell interaction; 15 Biomaterial strategies to modulate cancer; 15.1 Introduction; 15.2 Understanding cancer with biomaterials; 15.3 Molecular markers for cancer; 15.4 Biomaterials for cancer therapy; 15.5 Conclusion; 15.6 References; 16 3D cancer tumor models for evaluating chemotherapeutic efficacy; 16.1 Introduction; 16.2 Efforts to fight cancer; 16.3 Preclinical drug evaluation in cellular and animal models; 16.4 In vivo environment; 16.5 2D vs 3D culture systems; 16.6 3D tumor models; 16.7 Methods to culture multicellular tumor spheroids; 16.8 Conclusion; 16.9 References; 17 Nanotopography of biomaterials for controlling cancer cell function; 17.1 Introduction;17.2 The influence of surface topography and roughness of PLGA on cancer cells: creation of nanoscale PLGA surfaces; 17.3 The influence of nanoscale PLGA topographies on surface wettability and surface free energy; 17.4 The influence of PLGA nanotopographies on protein adsorption; 17.5 The impact of PLGA surface nanopatterns on cancer cell functions; 17.6 The impact of nanopatterns and LBL monolayers on cell functions; 17.7 Conclusions; 17.8 References; Index.